Compare · STIM vs SYK
STIM vs SYK
Side-by-side comparison of Neuronetics Inc. (STIM) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STIM and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 757.0x STIM ($148.6M).
- SYK has hit the wire 8 times in the past 4 weeks while STIM has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 6 for STIM).
- Company
- Neuronetics Inc.
- Stryker Corporation
- Price
- $1.89-3.57%
- $294.69+0.46%
- Market cap
- $148.6M
- $112.48B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 8
- Recent ratings
- 6
- 25
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest STIM
- B. Riley Securities initiated coverage on Neuronetics with a new price target
- NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
- SEC Form 8-K filed by Neuronetics Inc.
- Large owner Chernett Jorey bought $44,240 worth of shares (14,000 units at $3.16), increasing direct ownership by 0.13% to 10,602,988 units (SEC Form 4)
- SEC Form S-8 filed by Neuronetics Inc.
- SEC Form 10-Q filed by Neuronetics Inc.
- Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Neuronetics Reports Second Quarter 2026 Financial and Operating Results
- Neuronetics and Jorey Chernett Announce Shared Vision
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)